News
A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently ...
A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently ...
Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...
Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...
A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female ...
Explore more
Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.
The global Enzyme Replacement Therapy (ERT) market is poised for significant expansion, projected to reach USD 21.62 billion ...
According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...
2d
Dealbreaker on MSNSanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage VicebioThe deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results